Managing Triple-Negative Pregnancy-Associated Breast Cancer in Resource-Limited Settings
Pregnancy-associated breast cancer (PABC) occurs in roughly one in 3,000 pregnancies, with triple-negative breast cancer (TNBC) representing a particularly aggressive subtype. According to clinical data reported in Authorea (2025), successful management in resource-limited, non-tertiary settings relies on direct, multidisciplinary coordination between obstetric and oncology teams to bypass the lack of on-site advanced diagnostics like breast MRI or local genetic testing. While PABC typically presents at more advanced stages due to physiological breast changes, evidence indicates that guideline-concordant chemotherapy initiated after the first trimester does not significantly alter survival compared to non-pregnant patients.
Navigating Diagnostic Constraints
Diagnosis of PABC is often complicated by pregnancy-induced breast engorgement and nodularity, which can obscure tumors during physical exams. In a recent case study from Mauritius, a 35-year-old patient presented at 19 weeks’ gestation with a 1.5 cm axillary mass and a 2.5 cm breast lesion. Because the healthcare setting lacked on-site breast MRI and germline BRCA1/2 testing, the medical team relied on high-resolution ultrasonography and mammography with abdominal shielding to confirm a BI-RADS 5 malignancy.
The diagnostic protocol emphasized a “pregnancy-adapted” approach. Clinicians avoided ionizing radiation from CT scans, opting instead for abdominal ultrasound and brain MRI for staging.
Pro Tip: When managing suspected malignancy during pregnancy, prioritize ultrasound as the first-line imaging tool. It remains safe across all trimesters and provides high sensitivity for identifying suspicious vascularity and skin thickening.
Chemotherapy Safety During Pregnancy
Current oncology guidelines, as reaffirmed by the 2023 European Society for Medical Oncology (ESMO) expert consensus, consider chemotherapy generally safe after the first 12 weeks of gestation. In the Mauritius case, the patient received neoadjuvant chemotherapy starting at 19 weeks—well past the critical window of organogenesis. The regimen consisted of four cycles of epirubicin and cyclophosphamide (EC), followed by weekly paclitaxel.
However, rigorous monitoring remains non-negotiable. Fetal biometry and biophysical profiles must be tracked weekly to ensure appropriate growth and to detect early signs of intrauterine growth restriction, a known risk associated with taxane-based therapies.
Multidisciplinary Delivery Planning
The timing of delivery in PABC cases is a clinical balancing act. In the reported Mauritian case, the multidisciplinary team (MDT) scheduled an elective caesarean section at 34 weeks’ gestation. This decision was driven by oncological necessity rather than obstetric urgency. By delivering at 34 weeks, the team achieved three goals:
- Avoiding the risks of neonatal exposure to cytotoxic drugs during spontaneous labor.
- Allowing for a necessary treatment interval before delivery.
- Ensuring the mother could resume systemic therapy promptly in the postpartum period.
This coordinated handover between neonatologists and oncologists is essential for optimizing outcomes. Because cyclophosphamide and other chemotherapy agents are excreted in breast milk, breastfeeding is generally contraindicated during active treatment, requiring early patient counseling and emotional support.
Future Trends and Research Directions
While systemic chemotherapy remains the backbone of treatment, ongoing research aims to identify novel therapeutic targets for TNBC, which currently lacks the hormone-receptor-directed options available for other breast cancer subtypes.
A significant barrier remains the lack of standardized global data. Because PABC is rare, registries and collaborative international case reporting—such as the data provided in the 2025 Authorea report—are vital.
Did you know? Pregnancy-associated breast cancer is often diagnosed in later stages compared to non-pregnant breast cancer cases, not necessarily because the tumor biology is different, but often due to diagnostic delays caused by physiological changes in breast tissue.
Frequently Asked Questions
Is it safe to perform surgery for breast cancer during pregnancy?
Yes. According to current oncological standards, surgery is considered safe in all three trimesters. However, the MDT may choose to defer surgery until the postpartum period if neoadjuvant chemotherapy is required to manage the tumor size or nodal involvement first.
Does pregnancy make breast cancer more aggressive?
While PABC is often diagnosed in younger patients who may have more aggressive tumor subtypes (like TNBC), there is no definitive consensus that pregnancy itself accelerates tumor growth. Poorer outcomes, when observed, are often linked to diagnostic delays or the postponement of systemic treatments.
Can I breastfeed while undergoing chemotherapy for breast cancer?
No. Most chemotherapy agents, including cyclophosphamide and anthracyclines, are excreted in breast milk and pose significant risks to the infant. Physicians generally recommend the cessation of breastfeeding during active cytotoxic therapy.
Have you or a loved one navigated a complex pregnancy-related diagnosis? Share your questions or experiences in the comments below, or subscribe to our newsletter for the latest updates on oncology research and maternal health.
Worth a look